Axsome Therapeutics AXSM Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's accounts payable?
- Axsome Therapeutics (AXSM) reported accounts payable of $106.7M in Q1 2026.
- How has Axsome Therapeutics's accounts payable changed year-over-year?
- Axsome Therapeutics's accounts payable increased by 24.6% year-over-year, from $85.66M to $106.7M.
- What is the long-term trend for Axsome Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Axsome Therapeutics's accounts payable has grown at a 37.2% compound annual growth rate (CAGR), from $13.5M to $65.54M.
- What does accounts payable mean?
- Money the company owes to its suppliers for unpaid bills.
- How do you interpret accounts payable?
- An increase may suggest improved cash flow management through extended payment terms, while a sudden decrease could indicate cash constraints or aggressive vendor settlement.
- How does accounts payable compare across companies?
- Standard across all industries; typically benchmarked against days payable outstanding.